Letter: Early warning over Aids drug testing
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Sir: It is unsurprising that the 'Concorde' trial of AZT produced the results it did ('Shares tumble after trial of Aids drug', 3 April). Back in 1989-90, my colleague, John Creedy, and I raised many questions about the ethics, precepts and methodology of this trial, having had experience of taking the drug.
It was clear then that this trial was meant to underline Europe's supposed lead in virology, both theoretical and applied, and to boost Wellcome's exports. The trial also went some way towards addressing the medical profession's sense of emasculation in the face of asymptomatic HIV infection.
Our experience has shown the physical price to be paid for taking AZT: transfusions, tiredness and muscular pain. How anyone could have wished to visit those side-effects on patients who were well - except for a blood test - was, and remains, beyond our comprehension.
But something positive could come of the 'Concorde' disappointment. The Medical Research Council may finally be forced to produce an effective strategy in Aids research, one that is as much driven by seeking to treat and control the killer opportunistic infections in Aids as it is in glamorous (and potentially Nobel prize-winning) research for the 'magic bullet'.
Yours sincerely,
RICHARD BARKER
London, N7
3 April
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments